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Abstract
Background: The neuroprotein S100 released into the
circulation has been suggested as a reliable marker
for primary brain damage. However, safe identifica-
tion of relevant traumatic brain injury (TBI) may pos-
sibly be hampered by S100 release from peripheral
tissue. The objective of this study was to measure ear-
ly S100 levels using the Elecsys S100 immunoassay
for real-time assessment of severe TBI in multiple
trauma.
Methods: Consecutively admitted multiple trauma
patients (injury severity score G16 points) were strat-
ified according to the results of the initial cerebral
computed tomography (CCT) examination. S100
serum levels were determined at admission and at 6,
12, 24, 48 and 72 h after trauma. Data were correlated
to creatine phosphokinase (CK) and lactate dehydro-
genase (LDH) serum levels. Using receiver operating
characteristic (ROC) analysis, the discriminating pow-
er of S100 measurement was calculated for the detec-
tion of CCTq findings.
Results: Median S100 levels of CCTq patients (ns9;
37 years) decreased from 3.30 mg/L at admission to
0.41 mg/L 72 h after trauma. They revealed no signif-
icant differences to CCT– patients (ns18; 44 years),
but remained elevated compared to controls. Median
CK and LDH levels correlated with the corresponding
S100 levels during the first 24 h after trauma. ROC
analysis displayed a maximum area under the curve
of only 0.653 at 12 h after trauma. No significant dif-
ference was calculated for the differentiation between
CCTq and CCT– patients.
Conclusions: Measurements of S100 serum levels
using the Elecsys S100 immunoassay are not relia-
ble for the real-time detection of severe TBI in multi-
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ple trauma patients. Due to soft tissue trauma or bone
fractures, S100 is mainly released from peripheral
sources such as adipocytes or skeletal muscle cells.
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Introduction
Traumatic brain injury (TBI) represents the most seri-
ous diagnosis in multiple trauma patients, which cru-
cially affects the prognosis, particularly in patients up
to 45 years of age (1, 2). Apart from massive bleeding
due to vascular or parenchymal injuries, early mor-
tality within 24 h after trauma is mainly influenced by
severe TBI, whereas late mortality may be determined
by severe organ dysfunction up to multi-organ failure
(3, 4).
During primary diagnosis, as well as during further
hospital stay, neurological evaluation, for example,
using the Glasgow Coma Scale (GCS) score, of mul-
tiply injured patients is substantially affected by anal-
gesia sedation and relaxation. However, exact
determination of the neurological status by neuro-
functional examinations or measurements of bio-
chemical markers might lead to immediate
therapeutic strategies. Despite poor diagnostic quality
for diffuse brain damage in the early phase after TBI,
cerebral computed tomography (CCT) is generally
recommended as the method of the choice for pri-
mary diagnosis and follow-up (5, 6). However, patho-
logical CCT findings may not predict neurological
consequences. Although magnetic resonance imag-
ing is substantially more sensitive in TBI, it still plays
no crucial role for primary diagnosis owing to the low
availability of scanners. Therefore, an objective and
specific biochemical marker might be helpful, partic-
ularly in multiple trauma patients with additional TBI.
Increased S100 protein serum levels have previous-
ly been reported in cases of TBI, cardiac arrest and
cardiopulmonary surgery (7–11). Usually, S100 is
present in dimeric form (ab- and bb-heterodimers),
with two chains of equal molecular mass. Besides
release from Schwann cells of peripheral neurons, the
bb-heterodimer is predominantly located in astroglial
cells of the central nervous system (12). If these cells
are damaged structurally or by ischemia, S100 is rap-
idly released, leaking into the cerebrospinal fluid
(CSF) and secondarily across the blood-CSF barrier
into the circulation (13). The protein is eliminated by
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the kidney, and the biological half-life is reported as
30–113 min (14, 15).
An early peak for S100 levels in serum 20 min after
brain damage seems to reflect both cellular damage
and increased permeability of the blood-CSF barrier
in TBI patients (9). It has been suggested that elevated
S100 serum levels predict neurological long-term def-
icits in patients with TBI or hypoxic brain damage (10,
16). Recently, the newly-developed Elecsys S100
immunoassay with a processing time of 18 min was
introduced for the real-time detection of S100 protein
serum levels in patients with minor head injury (17,
18). However, some authors reported increased S100
levels in other than brain injury conditions. Small
amounts of S100 protein have been found in white
and brown fat tissue, skin, bone and skeletal muscle
tissue, as well as in melanoma and glioblastoma cells
(13, 19–21). Increased S100 levels were reported after
coronary artery bypass grafting (22) or cardiac sur-
gery (23), after bone fractures and thoracic contusions
without fractures (24, 25), and in cases of experimen-
tal hemorrhagic shock (26). Thus, the objective of our
study was to analyze the diagnostic validity of early
S100 serum levels using the Elecsys S100 immuno-
assay in multiple trauma patients for real-time assess-
ment of severe TBI.
Materials and methods
Study design and subjects
Between April and September 2001, all consecutive multiple
trauma patients who were admitted to our level 1 trauma
center and presented an injury severity score (ISS) G16
points were included in this prospective pilot study. After
initial CCT examination, the entire cohort was stratified into
two study groups for further statistical evaluation: a) patients
with cranial or intracranial findings (CCTq); and b) patients
without intracranial findings (CCT–).
Pre-hospital and in-hospital treatment of the multiple trau-
ma patients was performed according to the guidelines of
the German Society for Trauma Surgery. The study was
approved by the local Ethics Committee. Owing to analgesia
sedation and unconsciousness of all patients, agreement
was given retrospectively for the first blood sample and pro-
spectively for the second blood sample (within the first 6 h
after study entry) by the patients’ relatives, who were
instructed about the objective of the blood sampling.
Blood sampling and biochemical measurements
Following detailed clinical investigation and insertion of an
arterial catheter in the right or left radial artery, the first
blood samples (5 mL) were drawn directly after hospital
admission (approx. 60–90 min after trauma). Further blood
specimens were collected at 6, 12, 24, 48 and 72 h after trau-
ma. All samples were converted to serum by centrifugation
at 2700 g (3000 rpm) for 10 min at room temperature, and
frozen in aliquots at y708C until batch evaluation. For data
comparison, a control group was included, consisting of
venous blood samples from 20 healthy volunteers. No gen-
der or age-dependent differences or influence of the punc-
ture site on S100 protein have been detected in adults so far
(data not shown).
S100 serum levels were analyzed using the electroche-
moluminometric Elecsys S100 immunoassay (Roche Diag-
nostics, Penzberg, Germany). According to the manufac-
turer’s protocols, the fully automated test requires 18 min
and a probe volume of at least 20 mg/L. The lower detection
limit is 0.005 mg/L, and concentrations of up to 39 mg/L can
be measured without dilution. First, the analyte is sand-
wiched between two monoclonal antibodies (one is bioti-
nylated, the other is ruthenylated) directed against the
b-chain of the S100 dimer. Second, strepavidin-coated
microparticles are added and the immunocomplex binds to
the solid phase. In the measurement cell, unbound compo-
nents are removed and a defined voltage is used to initiate
the electrochemiluminescent reaction. The resultant light
emission is measured using a photomultiplier (21). Since the
b-chain of the S100 protein is selectively detected, this assay
measures both the S100A (S100ab) and the S100B protein
(S100bb) subunits.
For non-specific indication of cellular damage, levels of
serum creatine phosphokinase (CK; normal range -180 U/L
for males, -150 U/L for females) and lactate dehydrogenase
(LDH; normal range -250 U/L) were determined using Mod-
ular Analytics P800 immunoassay systems (Roche
Diagnostics).
Statistical analysis
All demographic and biochemical data are presented as
median and interquartile range (25th–75th percentiles).
Since the data were not normally distributed, Kruskal-Wallis
one-way analyses of variance (ANOVA) on ranks (Dunn’s
method) were applied to identify differences between the
five points of measurement (PM) as well as differences
between the study groups.
Pearson product moment correlations were calculated
between S100 and CK and LDH serum levels (SigmaStat ver-
sion 3.0; SPSS GmbH Software, Munich, Germany).
Using receiver operating characteristics (ROC) analysis
and determination of the area under the curve (AUC), the
discriminating power of S100 serum levels at every point of
measurement was calculated for the detection of posttrau-
matic intracranial lesions. The AUC is given as the mean,
standard error of the mean (SEM) and confidence interval
(CI; 5–95%). A two-tailed p-value of -0.05 was considered
to be significant.
Results
Demographic and clinical characteristics
From a total of 44 patients, 27 subjects (20 male, 7
female) with a median age of 41 years (33–53 years)
could be prospectively included during the observa-
tion period (Table 1). The remaining patients were pri-
marily excluded owing to incomplete data or incorrect
blood sampling. Of the patients included, 11 had sus-
tained multiple trauma due to falling from a height of
)3 m, 15 had been involved in traffic accidents (8 car
drivers or front seat passengers, 2 motorcycle drivers,
3 pedestrians and 2 bicycle drivers) and 1 patient had
jumped in front of a subway train in a suicide attempt.
The entire cohort, admitted to the emergency room
at a median time of 80 min (63–105 min) after trauma,
presented a median ISS of 38 points (26–45 points).
Four patients were intubated and sedated using anal-
gesia (GCS score of 3 points) at the scene, while the
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Table 1 Demographic and clinical characteristics of multiply injured CCTq and CCT– patients.
CCTq (ns9) CCT– (ns18) p*
Age, years 37 (32–55) 44 (30–53) NS
Male, % 67 72 NS
ASA score, points 2 (1–3) 2 (1–3) NS
ISS, points 49 (30–55) 34 (25–40) -0.05
Previous cerebrovascular disease, % – – NS
Creatinine G1.3 mg/dL (0.115 mmol/L) at admission, % 11 17 NS
Fluid balance at admission, mL 750 (500–1200) 850 (500–1400) NS
Time between trauma and admission, min 75 (60–95) 85 (65–105) NS
Length of stay, days 42 (15–98) 38 (21–110) NS
GOS score at discharge, points 3 (2–5) 4 (2–5) NS
Data are presented as median and interquartile range (25th–75th percentiles). NS, not significant; ASA, American Society of
Anesthesiologists; ISS, injury severity score; GOS, Glasgow Outcome Scale. *p-Value describes the statistical difference
between CCTq and CCT– patients in the Kruskal-Wallis one-way ANOVA test.
Figure 1 S100 serum levels of CCTq (ns9) and CCT–
(ns18) multiple trauma patients during the first 72 h after
trauma. Data are given as boxplot (median, interquartile
range) and confidence interval (5–95%); A, admission;
*p-0.05 in one-way ANOVA test between every point of
measurement and controls.
other 23 patients wGCS score of 14 points (12–15
points)x were intubated immediately after admission.
Eighteen patients showed inconspicuous CCT
examinations (CCT–), nine patients were evaluated as
CCTq. Seven patients had acute intracerebral lesions,
partially with subdural hematoma (ns3), which were
operated on using frontotemporoparietal decompres-
sion craniectomy and duraplasty. Two patients suf-
fered from increasing unilateral epidural hematoma,
which was relieved by frontotemporoparietal crani-
otomy and burr hole trepanation. In addition, CCT-
guided ventriculostomies with insertion of a
ventricular catheter were performed in every patient
to drain CSF and to measure the intracranial pressure.
Despite a clearly higher median ISS value, the
CCTq group revealed no significant differences
compared to the CCT– group for the following par-
ameters: age, gender, American Society of Anesthe-
siologists (ASA) score, previous cerebrovascular
disease, creatinine level G1.3 mg/dL (0.115 mmol/L)
and fluid balance at admission, time between trauma
and admission, length of hospital stay and neurolog-
ical status at discharge (Table 1).
S100 serum levels in multiple trauma patients
At admission, the median S100 serum level of the
CCTq group was clearly, but not significantly higher
(3.30 mg/L) than at 6 h after trauma (1.84 mg/L; Fig-
ure 1). Subsequently, it gradually decreased up to
72 h after trauma, albeit without significant
differences.
The CCT– group displayed a similar course of medi-
an S100 levels during the entire observation period,
without significant differences compared to the CCTq
group (Figure 1). Both groups showed significantly
higher median S100 serum levels than the control
group (0.05 mg/L).
The corresponding CK and LDH serum levels of the
study group (ns27) are shown in Table 2. Both par-
ameters were significantly higher compared to the
controls during the entire observation period. More-
over, significant Pearson correlations could be calcu-
lated between elevated S100 and CK and LDH serum
levels, especially during the first 24 h after trauma.
ROC curve analysis and AUC calculation for S100
serum levels
Analysis of the ROC curves for S100 serum levels dis-
played a maximum AUC of 0.653 (5–95% CI
0.427–0.870) 12 h after trauma (Table 3). However, dif-
ferences between CCTq and CCT– multiple trauma
patients were not statistically significant. Owing to the
small number of patients in both study groups, we did
not calculate a serum S100 cutoff value for the pre-
diction of CCTq findings.
Discussion
S100 protein is reported to be a sensitive and reliable
marker of cellular brain damage. It can be applied for
both primary diagnosis and long-term prognosis after
severe TBI (27–32). In the past, clinical studies pre-
dominantly used the Sangtec 100 luminescence
immunoassay, which is provided either for the LIA-
mat S100 or the LIAISON S100 analyzer (all from
DiaSorin S.p.A., Dietzenbach, Germany). Recently, the
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Table 2 S100, CK and LDH serum levels of 27 multiple trauma patients at admission and at 6, 12, 24, 48 and 72 h after
trauma.
S100, mg/L CK, U/L LDH, U/L
At admission 3.43 (2.21–6.91) 1166 (630–2485)* 466 (240–672)*
6 h after trauma 1.80 (0.62–2.83) 1840 (1110–2976)* 506 (312–810)*
12 h after trauma 0.91 (0.58–2.05) 1910 (1200–2544)* 479 (286–712)*
24 h after trauma 0.83 (0.37–1.65) 1232 (735–1880)* 345 (182–481)*
48 h after trauma 0.60 (0.24–1.04) 630 (277–1130)* 267 (188–403)
72 h after trauma 0.39 (0.17–0.59) 305 (156–532) 228 (146–358)
Controls 0.05 (0.04–0.06) 25 (15–44) 62 (35–101)
Data are presented as median and interquartile range (25th–75th percentiles). CK, creatine phosphokinase; LDH, lactate dehy-
drogenase. *p-Value describes significant Pearson product moment correlations between S100, CK and LDH serum levels.
Table 3 Diagnostic power of S100 levels at admission and at 6, 12, 24, 48 and 72 h after trauma.
S100 level AUC"SEM 5–95% CI p*
At admission 0.493"0.129 0.240–0.740 0.955
6 h after trauma 0.625"0.127 0.375–0.870 0.327
12 h after trauma 0.653"0.115 0.427–0.870 0.213
24 h after trauma 0.639"0.126 0.391–0.880 0.258
48 h after trauma 0.531"0.144 0.249–0.810 0.806
72 h after trauma 0.515"0.186 0.150–0.880 0.938
Data are presented as area under the curve (AUC), standard error of the mean (SEM) and confidence interval (5–95% CI). *p-
Value describes the statistical difference in the Kruskal-Wallis one-way ANOVA test when applying the median S100 level for
the differentiation between CCTq and CCT– multiple-injured patients.
rapid Elecsys S100 immunoassay was introduced for
the detection of S100 protein in patients with TBI (17,
18), in patients undergoing carotid stenting or surgery
(33), and for the follow-up and monitoring of therapy
in patients with malignant melanoma (21). Inter-meth-
od comparisons with the Sangtec 100 luminescence
immunoassay revealed good correlations with coef-
ficients ranging from 0.76 to 0.95 (21, 33).
In detail, significant correlations were shown
between circulating S100 serum levels at admission
and the extent of intracranial contusion in the initial
CCT. With respect to a suggested cutoff value of
0.12 mg/L for S100 measured by the Elecsys S100
immunoassay, primary brain damage after minor
head injury was diagnosed with a sensitivity of 100%,
but a clearly higher specificity of 67% and positive
predictive value of 40%, compared to the Sangtec
100 immunoassay using the LIA-mat S100 analyzer
(17). Only the presence, and not the exact type of
intracranial lesion, was significantly correlated with
the initial S100 serum level in those patients. In gen-
eral, the S100 protein is still regarded as a screening
parameter for primary diagnosis owing to its low
specificity, despite high sensitivity values. Initial GCS
score and Marshall computed tomography classifica-
tion exhibited similar positive predictive values in
terms of short-term prognosis, especially after severe
TBI, to increased S100 values (29, 34). However,
because of high negative predictive levels, acute
intracerebral lesions may be ruled out with the high-
est probability if the systemic concentration of S100
decreases below the cutoff level (18).
Following stratification according to the CCT find-
ings, no significant differences were noted in the pres-
ent study between multiple trauma patients with and
without TBI for median S100 serum level, length of
hospital stay or neurological status at discharge. The
initial S100 levels in patients with TBI (CCTq) were
even slightly lower than those without TBI (CCT–).
These biochemical observations have already been
reported by other authors, who mostly used the Sang-
tec 100 immunoassay on a LIA-mat S100 analyzer
(35, 36). Extracerebral sources of S100 release into the
systemic circulation obviously seem to play an impor-
tant role in multiple trauma patients. This hypothesis
is well supported by the significant Pearson moment
product correlations of S100 with CK and LDH serum
levels in our study, especially in the first 24 h after
trauma. S100 protein may be released in high
amounts from peripheral adipocytes, bone marrow or
skeletal muscle cells after major soft-tissue trauma,
thoracic contusions without fractures (0.5–4 mg/L) or
acute bone fractures (2–10 mg/L) (24, 25), or from Lan-
gerhans cells in cases of pancreatic injury (13, 37).
Even minor body stress during sports, i.e., controlled
running or heading, is supposed to lead to elevated
S100 levels. This has to be borne in mind to avoid
interpretation of findings as an indication of TBI (38,
39).
ROC analyses were performed for every measure-
ment time to demonstrate the diagnostic power of
S100 levels for the prediction of posttraumatic brain
injuries. As expected, the AUC at admission was
below the border of discrimination of 0.500; the AUC
was a maximum of 0.653 only 12 h after trauma.
Thus, the determination of S100 serum levels in mul-
tiple trauma patients using the Elecsys S100 immu-
noassay should not be considered as an additional
component for primary diagnosis. Unfortunately,
S100 levels could not differentiate between CCTq and
CCT– multiple trauma patients. However, measure-
ment of the neuroprotein S100 would be quite con-
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ceivable for the prediction of long-term prognosis,
which would have to be proven in further studies with
greater numbers of patients (35). Up to now, serial
measurements of S100 serum levels using the Elecsys
S100 immunoassay have been recommended only
for the follow-up and monitoring of therapy in
patients with malignant melanoma (21).
In conclusion, the measurement of circulating S100
serum levels using the Elecsys S100 immunoassay
is not reliable for the early detection of severe TBI in
multiple trauma patients. Due to soft tissue trauma or
bone fractures, S100 protein is mainly released from
peripheral sources such as adipocytes and skeletal
muscle cells. However, the significance of serum S100
for the estimation of long-term prognosis should be
clarified in a larger patient cohort.
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